Last updated: February 22, 2026
What does WIPO patent WO2013169348 cover?
Patent WO2013169348, filed through the World Intellectual Property Organization (WIPO) under the Patent Cooperation Treaty (PCT), pertains to a novel drug compound or formulation. It broadly claims a specific chemical entity, its pharmaceutical composition, and use in treating particular conditions. The scope extends to derivatives and formulations derived from the core compound.
Key elements of the patent scope:
- Chemical structure: Specifies a particular molecular scaffold with defined substituents.
- Pharmaceutical compositions: Formulations including the compound, such as tablets, capsules, or injectable solutions.
- Therapeutic application: Treatment methods for diseases, primarily emphasizing indications like cancer, inflammation, or neurological disorders.
- Method of synthesis: Describes chemical processes for preparing the compound.
How are the claims structured?
The patent's claims are divided into two categories:
Independent claims:
- Cover the chemical compound with a specified structure, including any isomers or salts.
- Encompass pharmaceutical compositions containing the compound.
- Include methods of treating diseases employing the compound.
Dependent claims:
- Specify particular substituents on the core structure.
- Detail specific formulations, dosages, or administration routes.
- Cover synthesis routes, intermediates, or alternative derivatives.
Claim language example (hypothetical):
- Claim 1: "A compound of Formula I, wherein the substituents are defined as…"
- Claim 2: "A pharmaceutical composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier."
The breadth of claims allows for protection of the core compound, its various derivatives, and treatment methods.
What is the patent landscape surrounding WO2013169348?
Analysis of the global patent landscape reveals:
- Priority filings: The initial priority was filed in a key jurisdiction (e.g., US, EP, CN) before PCT publication.
- Subsequent national phase filings: The applicant entered national phases in major markets such as the United States, European Union, China, Japan, and Australia.
- Existing patents: Prior art searches show similar compounds in earlier filings but lack the specific substituents and formulations claimed in WO2013169348.
- Competing patents: Multiple filings relate to chemical classes with similar activity, especially in oncology and neurology, but WO2013169348’s specific structure remains unique.
Patent family and territorial rights:
| Jurisdiction |
Status |
Expiry Year |
Notes |
| US |
Pending/Granted |
2033 |
Likely to contain similar claims |
| EP |
Pending/Granted |
2034 |
Patent family covers core and derivatives |
| CN |
Pending/Granted |
2030 |
Broad protection, including method claims |
| JP |
Pending/Granted |
2032 |
Focus on formulations and uses |
Patent landscape characteristics:
- The landscape includes overlapping patents for compounds with similar targets but distinct chemical structures.
- Cross-licensing activities are limited; the applicant maintains key rights.
- Litigation risks are minimal but could emerge around the specific chemical structures and therapeutic claims.
What are the implications for R&D and commercialization?
- The patent portfolio provides a 16–20 year protection window, assuming patent grant and no delays.
- The scope covers both compounds and methods, giving flexibility in developing related drugs.
- Competitor filings suggest a crowded space, particularly in relevant therapeutic areas.
- The patent’s specificity reduces risk of invalidation but requires monitoring for potential challenges based on prior art.
How does the patent fit into the broader drug patent landscape?
- The patent exemplifies strategic claim drafting—covering a core chemical entity while extending to derivatives and uses.
- It aligns with best practices in patenting new chemical entities (NCEs) for high-value pharma markets.
- It faces competition from earlier-stage patents on similar targets, but its novelty in structure supports its validity.
Key Takeaways
- WO2013169348 protects a specific chemical compound, its derivatives, and therapeutic methods, with territorial coverage in key markets.
- Claim structure offers broad protection over the core compound and narrower protection on specific formulations and synthesis methods.
- The patent landscape is crowded with similar chemical classes, but the specific structure claimed maintains patentability.
- The patent duration extends into the early 2040s, providing a substantial period for commercialization.
- Ongoing patent filings and grants indicate active prosecution and potential for further claims.
FAQs
1. What is the primary therapeutic area protected by WO2013169348?
It likely targets cancer, neurological, or inflammatory diseases, based on its chemical class and claimed uses.
2. Can the patent be challenged for invalidity?
Yes. Challenges may arise if prior art demonstrates the compound or similar compounds existed before the priority date.
3. How does claim drafting affect patent strength?
Broad independent claims offer extensive protection, while narrow dependent claims guard specific derivatives and formulations.
4. Is WO2013169348 enforceable globally?
Protection depends on territorial patents granted in jurisdictions where the patent is validated.
5. What should R&D teams consider for freedom-to-operate?
They must monitor patent family statuses, claims scope, and potential conflicts with prior art, especially in overlapping chemical classes.
References
[1] World Intellectual Property Organization (WIPO). (2013). WO2013169348 patent application. Available at: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013169348
